LMN-101 / Lumen Bio - LARVOL DELTA

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2 | N=42 | Completed | Sponsor: Lumen Bioscience, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: Lumen Bioscience, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Sep 2022 | Trial primary completion date: May 2022 ➔ Sep 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Lumen Bioscience, Inc. | N=84 ➔ 42

Enrollment change • Infectious Disease

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Lumen Bioscience, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2022 ➔ Dec 2022

Enrollment open • Trial completion date • Infectious Disease

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2; N=84; Not yet recruiting; Sponsor: Lumen Bioscience, Inc.; Trial completion date: Apr 2022 ➔ Jul 2022; Trial primary completion date: Jan 2022 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease

Researchers identify a drug that can treat Covid-19 (The Hindu Business Line) - "...4-Phenylbutiric acid (4-PBA) can avert mortality caused by respiratory failure due to cellular stress.The preliminary test of the drug, which was conducted on animal models, also showed promising results. Researchers believe that through this drug, they can tame the cytokine 'storm'....The study also identified the endoplasmic reticulum resident protein 'BiP'...as an indicator of cellular stress situations....This way, BiP levels, apart from determining the efficacy of 4-PBA treatment, could serve as early indicators of Covid-19 risk groups..."

Biomarker • Cytokine storm • New indication • Preclinical • Infectious Disease • Novel Coronavirus Disease

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers (clinicaltrials.gov) - P1; N=21; Completed; Sponsor: Lumen Bioscience, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2; N=84; Not yet recruiting; Sponsor: Lumen Bioscience, Inc.; Trial completion date: Apr 2021 ➔ Apr 2022; Initiation date: Feb 2020 ➔ Feb 2021; Trial primary completion date: Jan 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers (clinicaltrials.gov) - P1; N=21; Active, not recruiting; Sponsor: Lumen Bioscience, Inc.; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

LMN-101 in a Campylobacter Human Challenge Model (clinicaltrials.gov) - P2; N=84; Not yet recruiting; Sponsor: Lumen Bioscience, Inc.

Clinical • New P2 trial